

## Product datasheet for TL514011

## Eif4g2 Mouse shRNA Plasmid (Locus ID 13690)

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** Eif4g2 Mouse shRNA Plasmid (Locus ID 13690)

Locus ID:

DAP; DAP-5; E130105L11Rik; Na; Nat; Nat1; Natm1; p97 Synonyms:

pGFP-C-shLenti (TR30023) Vector: E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Puromycin

Selection:

Format: Lentiviral plasmids

Components: Eif4g2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 13690).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

BC040391, BC043034, BC056387, BC057673, BC064810, BC092521, BC127064, NM 001040131, RefSeq:

NM 013507, NM 001040131.1, NM 001040131.2, NM 013507.1, NM 013507.2, NM 013507.3,

BC010654, BC039274

UniProt ID: Q62448

Summary: Translation initiation is mediated by specific recognition of the cap structure by eukaryotic translation initiation factor 4F (eIF4F), which is a cap binding protein complex that consists of

> three subunits: eIF4A, eIF4E and eIF4G. The protein encoded by this gene shares similarity with the C-terminal region of eIF4G, that contains the binding sites for eIF4A and eIF3; eIF4G in addition, contains a binding site for eIF4E at the N-terminus. Unlike eIF4G which supports cap-dependent and independent translation, this gene product functions as a general repressor of translation by forming translationally inactive complexes. Transgene expression of the apolipoprotein B mRNA-editing enzyme (APOBEC-1) causes extensive editing of this mRNA, which could contribute to the potent oncogenesis induced by overexpression of APOBEC-1. In vitro and in vivo studies in human indicate that translation of this mRNA initiates exclusively at a non-AUG (GUG) codon. This also appears to be true for mouse. Two alternatively spliced transcript variants that encode different isoforms have been found for

this gene. [provided by RefSeq, Jul 2008]



OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com



shRNA Design:

These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a>. If you need a special design or shRNA sequence, please utilize our <a href="mailto:custom shRNA service">custom shRNA service</a>.

Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).